Trial Profile
A phase I study of PT523 [talotrexin] in patients with solid tumors
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 28 Nov 2013
Price :
$35
*
At a glance
- Drugs Talotrexin (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors Spectrum Pharmaceuticals
- 24 Aug 2005 New trial record.